Digital Mental Health: the Hurt, the Hype, the Hope
* Dr. Tom Insel, President and Co-Founder of Mindstrong Health
Top Brainnovation to measure Brain Health & Performance. The three Finalists were:
*Savonix— pitch by Greg Wong, VP Product Management
*HealthTech Connex — pitch by Dr. Ryan D’Arcy, President & Chief Scientific Officer
*NeuraMetrix (WINNER) — pitch by Jan Samzelius, Co-Founder & CEO
*Judged by: Dr. Adam Haim, Chief of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs at the National Institute of Mental Health (NIMH); Dr. David Barash, Chief Medical Officer and ED of Global Health at GE Foundation; Dr. Edward Kliphuis, Investment Director at Merck Ventures; Dr. Karen Postal, President of the American Academy of Clinical Neuropsychology (AACN)
*Álvaro Fernández, CEO and Editor-in-Chief of SharpBrains
*Sarah Lenz Lock, Senior Vice President for Policy at AARP and Executive Director of the Global Council on Brain Health (GCBH)
*Dr. April Benasich, Director of the Baby Lab at the Rutgers Center for Molecular and Behavioral Neuroscience
*Chaired by: Dr. Cori Lathan, Co-Chair of the World Economic Forum’s Council on the Future of Human Enhancement
Slidedeck supporting session held during the 2017 SharpBrains Virtual Summit: Brain Health & Enhancement in the Digital Age (December 5-7th). Learn more at: https://sharpbrains.com/summit-2017/
43. Top Brainnovations to measure Brain Health & Performance
Savonix — pitch by Greg
Wong, VP Product
Management
HealthTech Connex — pitch
by Dr. Ryan D’Arcy, President
& Chief Scientific Officer
NeuraMetrix — pitch by Jan
Samzelius, Co-Founder &
CEO
44. Judges
Dr. Adam Haim, Chief of the
Small Business Innovation
Research (SBIR) and Small
Business Technology Transfer
(STTR) Programs at
the National Institute of
Mental Health (NIMH)
Dr. Edward Kliphuis,
Investment Director at Merck
Ventures
Dr. David Barash, Chief
Medical Officer and ED of
Global Health at GE
Foundation
Dr. Karen Postal, President of
the American Academy of
Clinical Neuropsychology
(AACN)
46. PROBLEM
1,002
Neuropsychologists
are licensed to administer cognitive testing
43K+
patients per qualified clinician
That’s
43.4 million
people in the U.S. have been diagnosed with cognitive
disorders
47. SAVONIX as a SOLUTION
Designed for Research and Clinical
Applications
Range of cognition
Virtual clinician
Test behavior flags
Normed percentile reports
Mobile platform
Psychomotor control sensitive
Real time compliance monitoring
HIPAA, Part 11 compliant
48. Daily Digit Span
The Virtual Clinician ensures consistent, valid administration
through written and spoken instructions
ABOUT SAVONIX
49. Practice Mode ensures standard clinical administration
with adaptive feedback
ABOUT SAVONIX
50. Detailed test data delivered to the Savonix Dashboard for clinical review
ABOUT SAVONIX
51. CUSTOM
ANALYTICS
SCALABLE &
FLEXIBLE
PERSONALIZED
MEDICINE
OPTIMIZED
CLINICAL TRIAL
DESIGN
ENABLES DATA-
DRIVEN R&D
SaaS Licenses
Generate immediate revenue
and enable data collection for
Savonix Cognitive Database
HEALTHCARE
SYSTEMS
INSURANCE
COMPANIES
ACTUARIAL
COMPANIES
PHARMA &
BIOTECH
SAVONIX
COGNITIVE
DATABASE
PATIENT DATA
COLLECTION
DaaS Licenses
Deliver Value to 4 customer segments
• $10.00-$40.00/test range
• Enterprise business buys blocks of test
licenses
• Recurring revenue
HOW SAVONIX WORKS
52. CUSTOM
ANALYTICS
SCALABLE &
FLEXIBLE
PERSONALIZED
MEDICINE
OPTIMIZED
CLINICAL TRIAL
DESIGN
ENABLES DATA-
DRIVEN R&D
SaaS Licenses
Generate immediate revenue
and enable data collection for
Savonix Cognitive Database
HEALTHCARE
SYSTEMS
INSURANCE
COMPANIES
ACTUARIAL
COMPANIES
PHARMA &
BIOTECH
SAVONIX
COGNITIVE
DATABASE
PATIENT DATA
COLLECTION
DaaS Licenses
Deliver Value to 4 customer segments
• $10.00-$40.00/test range
• Enterprise business buys blocks of test
licenses
• Recurring revenue
HOW SAVONIX WORKS
54. MYLEA CHARVAT, PHD
CEO & Founder
MANAGEMENT TEAM
DAN KOGAN
VP Engineering
DAVID COOPER
COO
GREG WONG
VP Product
55. BRAIN HEALTH = OVERALL HEALTH
Monitor cognition relative
to baseline assessment
Detect cognitive
impairment early
Define optimal treatment
& management plan
Assess cognition at
multiple time points
HEALTHIER PEOPLE LIVE LONGER LIVES
59. Brain Vital Signs Framework (2012)*
+
Portable EEG technology
increasingly affordable
#1 Most Cited Article in Frontiers of Neuroscience
More than 200 Published Works; 44 Trademarks, Patents and Technical Reports
20+ years of clinical R&D
70+ years of research evidence
63. IMPACT
HEALTH INSTITUTIONS
Accuracy & Efficiency
Risk Mitigation
SOCIETY
Reduced Tax Burden
Global Health
INDIVIDUALS
Evaluation
Prevention
1 in 3 people will experience a
neurological condition in their lifetime
64. Upfront Charge: NeuroCatch Platform™
Recurring Revenue: Reports
Generated
Pay-Per-Scan
Subscription Model
Lease
Purchase
Future: Big Data Analytics
SALES
PROJECTION
Baseline Evaluation
Prognostics
$750M BVS
10%
$75M by 2020
Total addressable market:
Comparison (US alone)
65. GLOBAL MARKET
Neuro Healthcare Market: Over $30 billion within 5 years
(Grand View Research: Neuroscience Market Analysis 2015)
66. WE CAN HAVE A VITAL SIGN
FOR BRAIN FUNCTION
healthtechconnex.com l @brainvitalsigns
TRANSLATING ADVANCED NEUROSCIENCE R&D INTO PRACTICAL SOLUTIONS
69. 69
• Rid the world of passwords
• Discovered that typing cadence is the strongest
habit
Novelty
70. 70
• Rid the world of passwords
• Discovered that typing cadence is the strongest
habit
• “I bet you that can also be used to detect
Alzheimer’s”
Novelty
71. 71
• Rid the world of passwords
• Discovered that typing cadence is the strongest
habit
• “I bet you that can also be used to detect
Alzheimer’s”
• “You realize we have been looking for this for 30
years.” - Bob Mahley, Founder, Gladstone
Novelty
72. 72
Digital Bio-marker
•Install and forget
•Passive
•No tests
•No sensors
•Cadence NOT content
•Runs in background
•Fully automated
•Cloud-based
•Big data analytics
•Proprietary algorithms
•HIPAA compliant
•Sub-clinical (ms)
•Binary
•Continuous
•Predictive
•Personalized
All software and internet – infinite scalability and
great economics
+ =
77. 77
IP Approach
• Patents
• Trade Secrets
• Reverse engineering not possible
• Size of database
• 100M data points > 1B by end of Q1
• Disease fingerprints
78. 78
Impact
• Millions of patients enjoying a better life
• Early detection enabling pharma to develop drugs
leading to people enjoying life without suffering
from the disease or outright cures
79. 79
• Large unmet need
• Huge market
• Lots of well protected IP
• Very simple solution
• Internet and software = great financials
Summary